Wells Fargo & Company Issues Positive Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Key Points

• Wells Fargo raised its price target on Alnylam to $377 (from $376) and kept an "equal weight" rating, implying roughly a 24.7% upside from the stock's prior close.
• Q1 results beat expectations with $1.17 billion in revenue and $1.99 EPS (vs. $0.90 est), reflecting about 96% year‑over‑year revenue growth and supporting the bullish case on product uptake.
• Analyst sentiment is broadly positive (consensus "Moderate Buy" with an average target of $472.83), but recent insider selling and an outside review flagging a high risk of significant losses add downside and volatility concerns.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) had its price target lifted by equities researchers at Wells Fargo & Company from $376.00 to $377.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has an "equal weight" rating on the biopharmaceutical company's stock. Wells Fargo & Company's target price suggests a potential upside of 24.67% from the company's previous close.

A number of other research firms have also weighed in on ALNY. Bank of America reissued a "buy" rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. Jefferies Financial Group reissued a "hold" rating and set a $330.00 target price (down from $522.00) on shares of Alnylam Pharmaceuticals in a report on Monday, March 16th. Barclays started coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, January 28th. They set an "overweight" rating and a $527.00 target price on the stock. Raymond James Financial reissued an "outperform" rating and set a $472.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, January 12th. Finally, Truist Financial reduced their price objective on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a "buy" rating on the stock in a research note on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $472.83.

Alnylam Pharmaceuticals Trading Down 2.3%

ALNY traded down $7.10 during trading on Friday, reaching $302.39. 68,548 shares of the company's stock were exchanged, compared to its average volume of 1,305,320. Alnylam Pharmaceuticals has a one year low of $245.96 and a one year high of $495.55. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. The stock has a market capitalization of $40.35 billion, a PE ratio of 177.33 and a beta of 0.39. The firm has a fifty day moving average price of $320.11 and a two-hundred day moving average price of $377.45.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, topping analysts' consensus estimates of $0.90 by $1.09. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The firm had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period in the previous year, the firm posted ($0.44) EPS. The company's revenue for the quarter was up 96.4% compared to the same quarter last year. As a group, equities research analysts forecast that Alnylam Pharmaceuticals will post 6.75 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Jeffrey V. Poulton sold 2,206 shares of the business's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total transaction of $722,795.90. Following the transaction, the executive vice president owned 64,273 shares in the company, valued at $21,059,048.45. The trade was a 3.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the business's stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $319.73, for a total transaction of $528,193.96. Following the transaction, the executive vice president owned 21,860 shares in the company, valued at $6,989,297.80. The trade was a 7.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 38,656 shares of company stock worth $12,370,696. Corporate insiders own 0.86% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Mediolanum International Funds Ltd bought a new position in Alnylam Pharmaceuticals during the third quarter valued at about $11,389,000. Rakuten Investment Management Inc. bought a new position in Alnylam Pharmaceuticals during the third quarter valued at about $14,205,000. Generali Asset Management SPA SGR grew its position in Alnylam Pharmaceuticals by 6,368.0% during the third quarter. Generali Asset Management SPA SGR now owns 3,234 shares of the biopharmaceutical company's stock valued at $1,475,000 after buying an additional 3,184 shares during the period. Cerity Partners LLC grew its position in Alnylam Pharmaceuticals by 171.2% during the third quarter. Cerity Partners LLC now owns 27,429 shares of the biopharmaceutical company's stock valued at $12,507,000 after buying an additional 17,316 shares during the period. Finally, Campbell & CO Investment Adviser LLC bought a new position in Alnylam Pharmaceuticals during the third quarter valued at about $5,790,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Q1 beat — Alnylam reported Q1 revenue of $1.17 billion and EPS of $1.99, topping analyst estimates and showing ~96% revenue growth year-over-year; the results underpin the bullish case on product uptake and margin improvement. Alnylam Q1 earnings press release & transcript
• Positive Sentiment: Analyst support — Brokers maintain a positive stance (consensus ~“Moderate Buy”) and H.C. Wainwright reiterated a Buy, which can support investor confidence after the beat. Consensus recommendation article H.C. Wainwright note
• Neutral Sentiment: FY‑2026 revenue outlook roughly in line — the company issued FY‑2026 revenue guidance in the ~$5.3B–$5.8B range (around consensus), which moderates upside surprise potential; EPS guidance detail was less clear in published notes. Slide deck / guidance details
• Neutral Sentiment: Earnings call commentary — the full call transcript provides management color on growth drivers and pipeline cadence; useful for investors assessing sustainability of the beat. Earnings call transcript
• Negative Sentiment: Outside review raises downside risk — an external review highlighted that ALNY carries a high risk of significant losses, a regulatory/structural concern that can amplify volatility and prompt cautious positioning by institutional holders. Outside review warning

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.